

Figure S1. Cytotoxicity test by MTT assay on non-metastatic colon cancer cell line (HT-29) (A), metastatic colon cancer cell line (SW-620) (B) and normal human fibroblast cell line (PCS-201-010) (C) after treated with HRBE concentrations (0 – 10,000 μg/mL) for 24 h, 48 h and 72 h. The percentage of cell viability was determined as compared to an untreated condition. Data represented in the mean ± SD.




Figure S2. Cytotoxicity test by MTT assay on non-metastatic colon cancer cell line (HT-29) (A), metastatic colon cancer cell line (SW-620) (B) and normal human fibroblast cell line (PCS-201-010) (C) after treated with mitomycin C concentrations (0 – 10,000 $\mu\text{g/mL}$) for 24 h, 48 h and 72 h. The percentage of cell viability was determined as compared to an untreated condition. Data represented in the mean \pm SD.




Figure S3. Cytotoxicity test by MTT assay on SW-620 cells after treated with fraction of HRBE concentrations 0–10,000 μg/mL including (A) >50 kDa, (B) 50–30 kDa, (C) 30–10 kDa, (D) 10–3 kDa and (E) <3 kDa fractions, (F) Doxorubicin concentration 0–116 μg/mL and (G) Mitomycin C concentrations 0 – 50 μg/mL for 24 h, 48 h and 72 h. The percentage of cell viability was determined as compared to an untreated condition. Data represented in the mean ± SD.